Psychedelics Company Profiles

Click on a company name below to view key financials, press releases and interviews.

Pα+ Psychedelic Bulletin #182: Psychedelics Insiders’ Trump 2.0 Wishlist; Doblin Reflects on Lykos’ Strategy; Polish Psilocybin Study Scores $4M in FundingDecember 10, 2024
Psychedelics Insiders Draw Up Trump 2.0 Wishlist • Rick Doblin Reflects on Lykos’ Strategy as MAPS Settles with FDA • Polish Medical Research Agency Set to Provide PLN 16M ($4M) to Psilocybin Study • VA Issues Note on Psychedelics for PTSD; Officially Funds Psychedelics Study • Alleged Killer of UnitedHealth CEO Apparently Interested in Psychedelics • and more...
Inside the FDA’s Psychedelics Journey: Javier Muniz, MD on Breakthroughs, Challenges, and the Future of the FieldDecember 5, 2024
In our latest Pα+ interview, our Editor Josh Hardman speaks with Javier Muniz, MD, who recently left his post as Associate Director at the FDA’s Division of Psychiatry. In that role, Muniz was at the heart of the agency’s psychedelics learning journey and helped formulate its view on thorny topics in psychedelic drug development like functional unblinding and the role of psychotherapy. This interview is far-reaching and provides a unique look into both the mind of the regulator, but also Muniz’s own views on psychedelics, now that he is unencumbered by his position in the agency.
Psychedelic Drug Development Under Trump 2.0: Health Nominees Signal Uncertain FutureNovember 30, 2024
As Donald Trump rounds out his nominations for key positions in his incoming administration, we’re keeping an eye on how his health-related picks might impact the future of the psychedelics field, notably drug development and policy reform efforts.
Q3’24 Survey: What are Psychedelics Investors Concerned About?November 27, 2024
We take a close look at what psychedelics investors are most concerned about, using quantitative and qualitative data from our Q3'24 psychedelic investor survey.
Interviews: Meet the Team Who Challenged the DEA on DOI and DOCNovember 26, 2024
Meet the group of scientists, activists and lawyers who came face-to-face with the DEA to challenge the agency’s proposed scheduling of two phenethylamine psychedelics, DOI and DOC.

Psychedelics Company Profiles

Psychedelic Alpha

Quick Links

Newsletter

Subscribe to Our Free Newsletter

Join Pα+ for Premium Insights